Cytoplasmic Terminus of Vacuolar Type Proton Pump Accessory Subunit Ac45 Is Required for Proper Interaction with V₀ Domain Subunits and Efficient Osteoclastic Bone Resorption*§

Haotian Feng¹², Taksum Cheng¹³, Nathan J. Pavlos§, Kirk H. M. Yip¹, Amerigo Carrello¹, Ruth Seeber¹, Karin Eidne⁴, Ming H. Zheng³ and Jiake Xu¹⁴

From the ¹Molecular Orthopaedic Laboratory, Centre for Orthopaedic Research, School of Surgery and Pathology, University of Western Australia, Nedlands, Western Australia 6009, Australia and the ⁶Western Australia Institute for Medical Research, University of Western Australia, Nedlands, Western Australia 6009, Australia

Solubilization of mineralized bone by osteoclasts is largely dependent on the acidification of the extracellular resorption lacuna driven by the vacuolar (H⁺)-ATPases (V-ATPases) polarized within the ruffled border membranes. V-ATPases consist of two functionally and structurally distinct domains, V₁ and V₀. The peripheral cytoplasmically oriented V₁ domain drives ATP hydrolysis, which necessitates the translocation of protons across the integral membrane bound V₀ domain. Here, we demonstrate that an accessory subunit, Ac45, interacts with the V₀ domain and contributes to the vacuolar type proton pump-mediated function in osteoclasts. Consistent with its role in intracellular acidification, Ac45 was found to be localized to the ruffled border region of polarized resorbing osteoclasts and enriched in pH-dependent endosomal compartments that polarized to the ruffled border region of actively resorbing osteoclasts. Interestingly, truncation of the 26-amino acid residue cytoplasmic tail of Ac45, which encodes an autonomous internalization signal, was found to impair bone resorption in vitro. Furthermore, biochemical analysis revealed that although both wild type Ac45 and mutant were capable of associating with subunits a3, c, c¹, and d, deletion of the cytoplasmic tail altered its binding proximity with a3, c¹, and d. In all, our data suggest that the cytoplasmic terminus of Ac45 contains elements necessary for its proper interaction with V₀ domain and efficient osteoclastic bone resorption.

Osteoclasts are terminally differentiated multinucleated cells derived from the hematopoietic lineage that specialize in the solubilization of mineralized bone material (1). Upon attachment to the bone surface, the osteoclast undergoes a series of cytoskeletal reorganization and polarization events that culminate in the formation of a unique apical membrane known as the ruffled border. The ruffled border is the “resorptive organelle” of the osteoclast and is formed by the polarized targeting and fusion of acidified intracellular vesicles with the plasma membrane (2–4). These transport vesicles courier acidifying machineries as well as osteolytic enzymes such as, TRACP, cathepsin K, and matrix metalloproteinases (2, 5–7) to the ruffled border membrane domain where each cargo plays a discrete role in the resorptive function. Vacular H⁺-adenosine triphosphatases (V-ATPases)⁵ that line the ruffled border have long been established to play a vital role in the resorptive process. V-ATPases function to pump H⁺ into the underlying resorptive lacunae. This elevation in protons results in a highly acidified microenvironment that solubilizes the mineralized component of bone while providing optimal conditions for the degradation of the exposed organic phase by collagenolytic enzymes such cathepsin K (2, 7).

The importance of V-ATPase in osteoclastic bone resorption is exemplified by studies employing specific inhibitors and gene knock-out strategies to impair V-ATPase functions (8–11). Furthermore, mutations in the human TCIRG1 gene, which encodes for a osteoclast specific V-ATPase subunit, a3, results in infantile malignant osteopetrosis, thus substantiating the importance of V-ATPase in osteoclastic bone resorption (12–15). The structural and functional analyses of the V-ATPase complex in osteoclasts might facilitate the development of anti-resorptive agents targeting specifically the osteoclast V-ATPases (16).

V-ATPases belong to a unique class of ATPases responsible for the acidification of intracellular compartments in all eukaryotic cells (17, 18). In phagocytic cells such as macro-

---

* This work was supported by the National Health and Medical Research Council. The costs of publication of this article were defrayed in part by the advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The on-line version of this article (available at http://www.jbc.org) contains supplemental Figs. S1 and S2.

1 These authors contributed equally to this work.
2 Recipient the Australian Postgraduate Award.
3 Recipient of the Australian Postgraduate Award.
4 To whom correspondence should be addressed: Molecular Orthopaedic Laboratory, Centre for Orthopaedic Research, School of Surgery and Pathology, University of Western Australia, QEII Medical Centre, 2nd Floor M Block, Nedlands, 6009 WA Australia. Tel.: 618-9346-4051; Fax: 618-9346-3210; E-mail: jiake.xu@uwa.edu.au.

5 The abbreviations used are: V-ATPase, vacuolar H⁺-adenosine triphosphatase; BRET, bioluminescence resonance energy transfer; EYFP, enhanced yellow fluorescent protein; RLuc, Renilla luciferase; TRACP, tartrate-resistant acid phosphatase; PBS, phosphate-buffered saline; GST, glutathione S-transferase; RT, reverse transcriptase; GFP, green fluorescent protein; PBS, phosphate-buffered saline; TBS, Tris-buffered saline; M-CSF, macrophage colony-stimulating factor; OCL, osteoclast-like cell; IP, immunoprecipitation.
phases, V-ATPases are known to mediate cytoplasmic pH homeostasis and the acidification of most intracellular organelles. In addition, these macromolecular proton pumps are crucial to a number of fundamental cellular processes, including receptor recycling, protein processing and sorting, and microbial degradation (19, 20). Structurally, V-ATPases have been well modeled and are known to consist of two core functional domains, V₁ and V₀ (17, 18). The V₁ domain is responsible for ATP hydrolysis and is composed of a 570-kDa complex, which is made up of eight different subunits A–H, with a molecular mass of 70–14 kDa, whereas the V₀ domain functions as a proton translocation unit located across the limiting membrane.

The V₀ domain consists of a 260-kDa integral complex that is made of several subunits with molecular masses of 100–17 kDa (subunit a, d, c/c', and c''), with six copies of the c/c' subunits and single copies of a, d and c'' subunits (21). The largest subunit (subunit a) of 100 kDa of the V₀ is a transmembrane glycoprotein displaying characteristics of an N-terminal hydrophilic domain and a C-terminal hydrophobic domain with multiple potential transmembrane helices (22). Four isoforms (a1, a2, a3, and a4) of the 100-kDa subunit of the vacuolar proton-translocating ATPase have been identified (23–25). The second largest single subunit (subunit d) of 38 kDa is a hydrophilic protein containing no membrane helices (26) and has been found to be tightly associated with V₀ (27). The smallest subunits (subunits c/c' and c'') of 17–19 kDa are highly hydrophobic proteins with characteristics of proteolipids (18). In addition to the core subunits, a 45-kDa polypeptide, Ac45, has been reported to co-purify with the V₀ domain of V-ATPases from bovine adrenal chromaffin granules (28) and is predicted to be oriented toward the luminal side of the complex anchored to the membrane by a single α-helix in the C terminus of the polypeptide. Currently, the interaction of Ac45 with other subunits of V-ATPase complex and its biological function remain to be elucidated.

In the present study, using a subtractive hybridization approach we identified accessory V-ATPase subunit Ac45 in osteoclasts. Ac45 was differentially expressed during osteoclastogenesis and found to localize to the ruffled border and endosomal compartments in polarized osteoclasts. To investigate the potential role of Ac45 in osteoclasts, we expressed a cytoplasmic terminus deletion mutant (Ac45ΔC) that lacks the 26-amino acid internalization signal. Overexpression of Ac45ΔC in osteoclasts showed a dramatic reduction on bone resorption. Furthermore, using immunoprecipitation and bioluminescence resonance energy transfer (BRET) assays, we demonstrate, for the first time, that Ac45 specifically associates with the V₀ domain subunits a3, c, and c''. Interestingly, deletion of the C-terminal tail (Ac45ΔC) altered Ac45 association with subunits a3, c'', and d. In all, our studies suggest that the cytoplasmic terminus of Ac45 is required for its proper interaction with V₀ domain subunits and plays an important role in osteoclastic bone resorption.

EXPERIMENTAL PROCEDURES

Reagents and Antibodies—Transferrin Alexa Fluor 546, Lysotracker, and rhodamine-conjugated phalloidin were purchased from Invitrogen. Restriction enzymes and reverse transcriptase were purchased from Promega (Sydney, Australia), and DNA polymerase was from GeneWorks (Adelaide, Australia). GST-rRANKL-160–318 recombinant proteins were expressed and purified in our laboratory as previously described (29). Anti-GFP rabbit polyclonal antibodies were obtained from Abcam (Sapphire Bioscience Pty. Ltd., Sydney, Australia). Anti-FLAG and anti-c-Myc monoclonal antibodies were purchased from Sigma. A rabbit anti-Ac45 antibody raised against the last 12 amino acids of mouse Ac45 was kindly provided by Dr. E. Jansen (Department of Animal Physiology, University of Nijmegen, The Netherlands). The anti-Ac45 antibody was precleared by absorption with bacterial cell lysates and purified by protein–agarose beads (30). Antibodies against the a3 subunit of the V-type H⁺-ATPase were raised in guinea pigs and were kindly provided by Dr. Jens C. Fuhrmann (Zentrum fur Molekuleare Neurobiologie Hamburg, ZMNH, Universität Hamburg, Falkenried, Hamburg, Germany) (31). Rabbit polyclonal anti-d2 antibodies were raised against GST-d2 peptide antigen produced in our lab and affinity-purified.

PCR-selected Subtractive Hybridization and Expression of Ac45 by RT-PCR—The cDNA-subtracted library was constructed using RAW264.7 (driver) and RAW264.7-derived osteoclasts (tester) according to the procedures of the Clontech PCR-Selected cDNA subtractive hybridization kit (Clontech). The cDNA sequence of the subtracted cDNA library was determined using BigDye termination reaction mix and automated sequencer (PerkinElmer Life Sciences). To determine the tissue distribution of Ac45 mRNA expression in normal mice, total RNA was isolated from various snap-frozen tissues using RNAzol solution according to the manufacturer’s instructions (Ambion Inc., Austin, TX). For RT-PCR, single-stranded cDNA was prepared from 2 μg of total RNA using reverse transcriptase with an oligo(dT) primer. Cycle-dependent PCR was carried out using 2 μl of each cDNA (94 °C, 40 s; 54 °C, 40 s; and 72 °C, 40 s) with mouse Ac45 primers (forward, 5'-AGATCTCCACATACTGATGGCGGCAACAGT-3'; reverse, 5'-AGTCTTCCACAATCTGGGGTCAAAGTG-3'). Primers for3 (forward, 5'-GGATCCGAATTCATCATGGGCTCTATGTTC-3'; reverse, 5'-GGATCTCTTACACTAGTCAAAGGTCACCTTGCAACGT-3'), c (forward, 5'-GGATCCGAATTCATGCTTGAGACTGCAGAG-3', 5'-CCCCCCTAGTCACCCATCTTCA-3'), d1 (forward, 5'-GGATCCGAATTCATGCTTGAGACTGCAGAG-3', 5'-CCCCCCTAGTCACCCATCTTCA-3'), and d2 (forward, 5'-GGATCCGAATTCATGCTTGAGACTGCAGAG-3', 5'-CCCCCCTAGTCACCCATCTTCA-3').

Construction and Expression of GST-Ac45 Fusion Protein—The mouse Ac45 gene was PCR-amplified using mRNA isolated from mouse osteoclasts with the Ac45 primers (forward,
Ac45 in Osteoclastic Bone Resorption

5'-AGATCTACCATGATGGCCGACAGT-3'; reverse, 5'-AGATCTTCCAATCTGGGTCAAAGTG-3'). The PCR product was cloned into a pCR 2.1 T/A cloning vector to make pCR2.1-Ac45, and its sequence was confirmed. A 606-bp BamHI and EcoRI restriction fragment was then subcloned into the BamHI and EcoRI sites of the pGEX-3X to make pGEX-3X-Ac45. To express glutathione S-transferase (GST) fusion proteins, plasmid pGEX-3X-Ac45 was transformed into the bacterial strain BL-21. Following growth in Luria-Bertani medium containing 100 μg/ml of ampicillin for 3 h at 30 °C, isopropyl β-D-thiogalactopyranoside was added to a final concentration of 0.1 mM, and the bacterial culture was incubated for a further 4 h at 30 °C. Bacteria were harvested and lysed in a standard SDS sampling buffer (Bio-Rad).

Immunofluorescence and Confocal Analysis—For immunofluorescent staining, RAW264.7 cells or osteoclasts cultured on glass coverslips or dentine slices were fixed with 4% paraformaldehyde in PBS for 10 min at room temperature and washed four times with PBS. Fixed cells were treated with 0.1% of Triton X-100 for 5 min and washed. The anti-Ac45 antibody was added at final dilution of 1:100 and incubated for 1 h at room temperature. A secondary antibody labeled with fluorescence (Sigma) was used at final dilution of 1:300. For the subcellular localization of Ac45, endocytic or lysosome tracers were added to the RAW264.7 cells. Lysotracker was added to cell culture at a final concentration of 1 μM and incubated for 30 min. Transferrin Alexa Fluor 546 was added to a final concentration of 20 μg/ml and incubated for 30 min. For co-localization of Ac45 and a3, the anti-Ac45 antibody was added at final dilution of 1:100, and the anti-a3 was added at a final dilution of 1:200. Secondary antibodies were labeled with rhodamine for the anti-Ac45 antibody and fluorescence for the anti-a3 antibody, respectively. Fluorescent images were collected on a Bio-Rad MRC 1000/1024 UV laser scanning confocal microscope.

Western Blot—The proteins were separated on SDS-PAGE gels and then transferred to nitrocellulose by electroblotting as previously described (30). The blots were incubated in 5% skim milk in Tris-buffered saline (TBS; 0.05 M Tris, 0.15 M NaCl, pH 7.5) for 1 h and probed with rabbit anti-Ac45 polyclonal antibody, rabbit anti-d2 antibody, mouse anti-α-tubulin antibody, or rabbit anti-GFP antibody at final concentrations of 1:200, 1:1000, 1:2500, or 1:2000 in TBS containing 5% skim milk, respectively. The blots were washed 10 min with TBS three times and incubated with peroxidase conjugated IgG (Sigma) at 1:1000 in TBS containing 5% skim milk. Following three washes with TBS, the antibody reactivity was detected by ECL (Amersham Biosciences) according to the manufacturer’s instructions.

Production of Retroviruses—Retroviral vectors pMx-Ac45-IRES-EGFP and pMx-Ac45ΔC-IRES-EGFP were constructed by inserting full-length mouse cDNA of Ac45 and mutated Ac45ΔC, in which the 26-residue cytoplasmic tail (amino acids 437–463) of Ac45 is truncated, into pMX-IRES-EGFP vector (kindly provided by Dr. Kitamura, University of Tokyo). Retrovirus packaging was performed by transfection of the pMX vectors into packaging cell line plat E cells (32). Virus stocks were prepared by collecting the media from cultures 48 h after transfection.

Osteoclastogenesis and Retroviral Transduction—To generate osteoclast precursors, freshly isolated bone marrow cells were cultured for 3 days with 10 ng/ml M-CSF in α-modified essential medium supplemented with 10% fetal calf serum. Adherent cells were used as osteoclast precursors. For retroviral transduction, the osteoclast precursors were transfected with viral supernatants in the presence of polybrene (2 μg/ml). On day 2 of transduction, puromycin (2 μg/ml) was added into the culture to select gene-integrated cells. The cells were then cultured with M-CSF (10 ng/ml) and RANKL (the receptor activator of NF-κB ligand; 100 ng/ml) for 5 or 6 days at 37 °C in an atmosphere of 5% CO2/95% air and were fed every 2 days by replacing half of the spent medium with fresh medium and M-CSF and RANKL. The cells were fixed and stained for TRACP activity to identify osteoclasts. TRACP+ cells containing ≥3 nuclei were scored as osteoclasts or osteoclast-like cells (OCLs). Osteoclastic bone resorption assays were done as previously described (33).

Immunoprecipitation—For co-immunoprecipitation of Ac45 and Ac45ΔC mutant with V5 subunit a3, COS-7 cells were seeded to a density of 2 × 106 in 10-cm Petri dishes and 24 h later were co-transfected with 2 μg each of Ac45-EYFP and Myc-a3 or with Ac45ΔC-EYFP with Myc-a3 using PolyFect transfection reagent (Qiagen). Twenty four hours post-transfection, medium containing transfection complexes were removed and replaced with fresh Dulbecco’s modified Eagle’s medium and incubated for further 24 h. After 24 h the cells were washed twice in ice-cold 1 × PBS prior to lysis with 1 ml of lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, and 1% Nonidet P-40) containing Complete protease inhibitor mixture (Roche Applied Science). The lysates were scraped into 1.5-ml tubes on ice, passed through a 23.5-gauge needle, and cleared by centrifugation at 14000 rpm at 4 °C for 30 min. The lysates were then precleared with incubation with Sepharose G bead slurry (GammaBind G Sepharose; Amersham Biosciences) for 2 h at 4 °C. One milligram of total protein was then incubated at 4 °C overnight with 5 μg of anti-GFP antibody (Abcam; Sapphire Bioscience). Antibody-bound proteins were then captured by incubation with washed (twice with lysis buffer) Sepharose G beads at 4 °C for 2 h. Protein-bound beads were then washed three times with lysis buffer, and proteins were eluted with the addition of 2× SDS sampling buffer containing 2% β-mercaptoethanol. Boiled samples were separated on 10% SDS-polyacrylamide gel followed by overnight transfer to nitrocellulose membrane (Amersham Biosciences). After overnight transfer, the membranes were blocked with 5% (w/v) skim milk powder in TBS-T (10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1% (v/v) Tween 20) and then probed with anti-Myc (Sigma) antibody diluted 1/1000 in 1% (w/v) skim milk powder in TBS-T. After washing three times with TBS-T, the membranes were incubated with horseradish peroxidase-conju-
gated secondary antibody diluted 1/5000 in 1% (w/v) skim milk powder in TBS-T. The membranes were then developed using the enhanced chemiluminescence system (Amer- sham Biosciences).

**BRET Assays**—PCR-based methodology was used to generate the following constructs for BRET assays. These include pcDNA-Rluc-V-ATPase-a3, pcDNA-Rluc-V-ATPase-c, pcDNA-Rluc-V-ATPase-c*, pcDNA-Ac45-EYFP, and pcDNA3.1-Ac45 mutant-EYFP. Primers a3 forward (5′-GGATCCGATTCACTAGTGGGCTATGTT-3′) and a3 reverse (5′-GGATCCTCTAGACTAGTCCAC-AGT-3′) were used to make pcDNA-Rluc-V-ATPase-a3. Primers c forward (5′-GGATCCGATTCACTAGTGGGCTATGTT-3′) and c reverse (5′-GGATCCTCTAGACTAGTCCAC-AGT-3′) were used to make pcDNA3.1-Rluc-V-ATPase c. Primers c* forward (5′-AGATCCGATTCACTAGTGGGCTATGTT-3′) and c* reverse (5′-GGATCCTCTAGACTAGTCCAC-AGT-3′) were used to make pcDNA-Rluc-V-ATPase-c*. Primers d1 forward (5′-GGATCCGATTCACTAGTGGGCTATGTT-3′) and d1 reverse (5′-GGATCCGATTCACTAGTGGGCTATGTT-3′) were used to make pcDNA3.1-Rluc-V-ATPase d. Primers Ac45 forward (5′-AGATCTTACATGTCGTTCTTCCCGGA-3′) and Ac45 reverse (5′-AGATCTTACATGTCGTTCTTCCCGGA-3′) were used to make pcDNA-Rluc-V-ATPase-c. Primers e forward (5′-AGGATCCGATTCACTAGTGGGCTATGTT-3′) and e reverse (5′-GGATCCTCTAGACTAGTCCAC-AGT-3′) were used to make pcDNA3.1-Rluc-V-ATPase-c, pcDNA-Rluc-V-ATPase-c*, pcDNA-Ac45-EYFP, and pcDNA3.1-Ac45 mutant-EYFP. Primers Ac45 showed significant overlap with V-ATPase subunit a3, and Ac45 for-}
confirming its association with the V-ATPase complex in osteoclast-like cells (Fig. 3, A–F). In bone resorbing osteoclasts, Ac45 co-localized with transferrin consistent with the localization observed on glass (Fig. 3, G and H). This overlap was largely toward the ruffled border region of the osteoclast (Fig. 3I). In addition, Ac45 showed significant overlap with filamentous actin (F-actin) at the sealing zone, suggesting that Ac45 is targeted toward the ruffled border membrane in polarized osteoclasts (Fig. 3, J–L). Taken together, these findings indicate that Ac45 associates with endocytic compartments within the ruffled border region of osteoclasts during bone resorption.

Deletion of the Cytoplasmic Tail of Ac45 Impairs Osteoclastic Bone Resorption—It is well accepted that during bone resorption V-ATPases accumulate in the ruffled border membrane of osteoclasts whereby they actively secrete border membrane to dissolve the underlying mineralized bone. Given the fact that Ac45 also localized to the ruffled border region of osteoclasts, we reasoned that Ac45 might play an important role in the V-ATPase-mediated bone resorption process. To address this possibility we adopted a mutational approach and deleted the 26-amino acid cytoplasmic tail of Ac45 (Ac45ΔC). The 26-residue cytoplasmic tail of Ac45 has been previously shown to contain autonomous targeting information distinct from previously described routing determinants (38). Thus, we hypothesized that the cytoplasmic tail may be important for Ac45 association and function with the V-ATPase complex and therefore osteoclastic bone resorption.

To explore this notion, retroviral constructs (Ac45-IREs-GFP and Ac45ΔC-IREs-GFP) were generated and retroviruses were produced using the plat E packaging cell line (Fig. 4A). Bone marrow cells were subsequently transduced with the virus, and up to 90% of cells were deemed to be GFP positive (+) for each group (data not shown). Following transduction, osteoclast formation was induced through the addition of M-CSF and RANKL. After 7 days, resulting multinucleated cells were fixed and stained for TRACP activity. Approximately 95% of all osteoclasts were GFP (+) in each group as judged by confocal microscopy (Fig. 4, B, E, and H). In addition, quantitative analysis of multinucleated (>3 nuclei/cell) TRACP positive cells yielded no significant difference among the three retrovirally transduced groups (Fig. 4, C, F, I, and K). Next, we examined whether overexpression of Ac45 or Ac45ΔC affected osteoclastic bone resorption. To this end, retrovirally transduced bone marrow cells were cultured on the dentine slices in the presence of M-CSF and RANKL. After 2 weeks, multinucleated cells were subsequently removed, and resorption lacunae were visualized under scanning electron microscopy.
microscopy. As shown in Fig. 4 (D, G, and L), no significant difference in bone resorption was observed in osteoclasts transfected with GFP or wild type Ac45. In contrast, osteoclasts expressing Ac45ΔC displayed a dramatic reduction in bone resorption capacity when compared with GFP and Ac45 groups (Fig. 4, J and L). Notably, resorption was not completely abolished, probably reflecting the presence of untransfected osteoclasts, given that the population is 95% GFP-positive. In addition, to explore the molecular mechanism of impaired osteoclastic bone resorption by Ac45ΔC, we tested whether over-expression of Ac45ΔC in osteoclasts could result in mislocalization of V₀ a3 subunit. By using specific anti-a3 antibody, immunostaining analysis showed that there is no observable difference among the EYFP, Ac45-IRES-GFP, and Ac45ΔC-IRES-GFP osteoclasts (supplemental Fig. S2, A–I). Together, these data hint that the cytoplasmic tail of Ac45 may play an important role in osteoclastic bone resorption.

Ac45 Specifically Associates with V₀ Subunits of the V-ATPase Complex—Ac45 has been previously reported to co-purify with the V₀ sector of the V-ATPase complex (28). However, its precise association with specific subunits of the V₀ domain of the V-ATPase complex has not yet been established. Because of Ac45 apparent function in osteoclast bone resorption, we sought to clarify its association with the V-ATPase complex in an effort to shed further insight into its potential role. To this end, we examined the association of Ac45 with other V₀ subunits. Having established that Ac45 co-localizes with a3 in osteoclasts, we initially confirmed this physical association by co-immunoprecipitation. For this purpose COS-7 cells were co-transfected with Ac45-FLAG or Ac45ΔC-FLAG and a3-Myc, EYFP-c, or EYFP-c”, and immunoprecipitation was carried out 48 h post-transfection. Following immunoprecipitation (IP), bound a3, c, or c”, proteins was detected using an anti-Myc or anti-GFP antibody, respectively. As shown in Fig. 5B, both Ac45 and Ac45ΔC interacted with a3, suggesting that the C terminus is not required for its association with the a3 subunit. Similarly, the c and c” subunits were also immunoprecipitated with Ac45 as well as with the C-terminal deletion mutant. These data indicate that both Ac45 wild type and the C-terminal truncation mutant Ac45ΔC is incorporated into the V₀ complex. Considering that all these V₀ subunits are membrane-bound proteins, we also co-transfected Ac45 or Ac45ΔC with Rab3D gene encoding a membrane bound vesicle protein (3) into COS-7 cells to exclude the possibility of nonspecific interactions shown in these

![Image of the page](https://example.com/image_url)
Although IP provides important confirmation of protein-protein interaction, it does not quantitatively reflect the protein association in living cells. Therefore we examined this interaction in live COS-7 cells by BRET analysis. EYFP-tagged Ac45 or Ac45ΔC and RLuc-tagged V0 a3, c, c’, or d fusion proteins (Fig. 5C) were co-expressed in COS-7 cells, and the BRET ratios were determined by measuring the RLuc activity and EYFP activity. As shown in Fig. 5E, the ratios of Ac45-EYFP and RLuc-a3 were significantly higher compared with EYFP control, again confirming Ac45 association with the a3 subunit. In addition, Ac45-EYFP wild type was found to associate with RLuc-c and RLuc-c’, but not RLuc-d. The BRET signals were highest between Ac45 and the c’ subunit followed by subunits c and a3, suggesting that Ac45 is most tightly associated with the c’ subunit of the V0 domain. Like Ac45-EYFP, Ac45ΔC-EYFP also interacted with V0 subunit c; however, this association is markedly lower with subunit c’ as compared with wild type Ac45, suggesting that the cytoplasmic tail of Ac45 maybe part of a specific binding element that is required for efficient interaction with subunit c’, hence a reduction but not total attenuation of interaction between the two subunits. Furthermore this reduced association of Ac45ΔC with the c’ subunit may also account for the impaired resorptive activity of osteoclasts overexpressing Ac45ΔC. Interestingly, however, Ac45ΔC showed a slight increase in BRET ratio with a3 and d1 as compared with wild type. This enhancement may reflect conformational changes in Ac45 because of a deletion at its C terminus. Again to test for specificity of the BRET assay, EYFP-Rab3D was used as a control. EYFP-Rab3D did not interact with any of the RLuc-tagged V0 subunits (data not shown).

**DISCUSSION**

Generation of a continuous proton gradient across the osteoclastic ruffled border domain is critical to its resorptive function (2, 5). Previous studies have shown that various V-ATPase subunits play important roles in osteoclast differentiation and function (9, 24, 39). Targeted dis-
Ac45 in Osteoclastic Bone Resorption

Figure 4. The effect of overexpression of Ac45 or Ac45ΔC on osteoclast formation and osteoclastic bone resorption. A, schematic representation of GFP, Ac45-IRES-GFP, and Ac45ΔC-IRES-GFP constructs. Bone marrow cell derived osteoclasts transduced with GFP (B–D), Ac45-IRES-GFP (E–G), or Ac45ΔC-IRES-GFP (H–J) retroviruses. Transduced cells were seeded on glass coverslips or 96-well culture plates or bone slices in the presence of RANKL and M-CSF. After 7 days on the glass coverslips or the culture dishes, the cells were fixed and processed for confocal analysis (B, E, and H) or TRACP staining (C, F, and J). In 96-well culture plates, TRACP positive OCLs were counted, and no significant difference was observed between all groups (K). The cells on the bone slices were removed after 14 days of culture, and resorptive lacunae were examined by scanning electron microscopy (D, G, and J). Quantitative analysis shows the percentage of bone slice surface occupied by resorption lacunae (L). ***p < 0.001.

ruption of the ATP6I gene in mouse that encodes the osteoclast specific a3 subunit of the vacuolar proton pump, termed OC116, confers a severe osteopetrotic phenotype because of the inability of the osteoclast-like cells to carry out resorption lacunae acidification (9). Furthermore, mutations in the TCIRG1 gene, which encodes for the human a3 subunit, have been reported in patients affected by infantile malignant osteopetrosis, a heterogeneous autosomal recessive disorder of bone metabolism (12–15). In addition, recent study has shown that V0 subunit d2 is important for osteoclast fusion (37). Although these studies highlight the importance of V-ATPase activity in osteoclast function, the precise role(s) of the individual subunits that comprises the V-ATPase complex in osteoclast differentiation and function remains to be elucidated.

In this study, using a subtractive hybridization approach, we identified accessory V-ATPase subunit Ac45 in osteoclasts. Furthermore, Ac45 was found to be differentially expressed during osteoclastogenesis, albeit at a lesser degree than that of V-ATPase subunits a3 and d2. By immunofluorescence, Ac45 was found to co-localize with pH-dependent transferrin, consistent with previous reports indicating that V-ATPases are enriched on endocytic compartments (18, 40). This finding is also in line with previous localization studies of Ac45 in the Xenopus (38). In addition, Ac45 was found associate with the ruffled border and sealing zone of resorbing osteoclasts as evidenced by its significant co-localization with the a3 V-ATPase subunit and F-actin. These findings are consistent with the notion that V-ATPases are transported to the ruffled border via actin filaments (2, 41–43). Studies by Nakamura et al. (42) demonstrated that V-ATPases associate with the detergent-insoluble actin cytoskeleton of osteoclast and that this interaction is crucial for osteoclast function (42). In addition, V-ATPases have been shown to bind to actin filaments and to be transported to the polarized ruffled border membrane by actin-myosin II contraction (41). More recently, V1 subunits B and C have also been shown to directly associate with filamentous actin in osteoclasts (44, 45). Whether Ac45 targeting is also actin-dependent will be the focus of future investigations.

Knock-out of specific V-ATPase subunits commonly result in embryonic lethality (46–49), pointing to an essential role for the V-ATPases in early embryonic development. Targeted disruption of the Ac45 gene in mice has been reported to inhibit blastocyst development (50), indicating that Ac45 is indispensable for cell functioning and survival. It has previously been shown that the cytoplasmic tail of Ac45 contains autonomous targeting information that is capable of mediating endocytosis of Ac45 from the cell surface to vacuolar structures (38). Therefore in an effort to investigate the potential function of Ac45 in osteoclasts, we overexpressed a deletion mutant of Ac45 lacking the C-terminal domain in osteoclasts and examined its effect on bone resorption. Strikingly, overexpression of Ac45ΔC was found to dramatically reduce osteoclastic bone resorption, indicating that the C-terminal domain is an important requirement for osteoclastic function. Unfortunately because of the lack of appropriate reagents, at this stage we are unable to determine whether the deletion of the C-terminal domain impair the targeting of Ac45 to the ruffled border or the proton translocation of the V-ATPase itself. Immunostaining analysis using specific antibody to V0 subunit a3 suggests that this C-terminal deletion of Ac45 seemed not
Previous studies indicate that Ac45 co-purifies with the $V_o$ domain of the V-ATPase complex in bovine chromaffin granules (28). However, the precise localization and subunit(s) association of Ac45 within the V-ATPase complex remains unclear. Ultrastructural analysis of the V-ATPase complex has previously suggested that Ac45 may represent a globular density oriented toward the luminal side $V_o$ domain subcomplex (51). This proposed structure was found to be associated and centered in the asymmetric ring composed of six c subunits and one $c''$ subunit, with the a subunit seen as peripheral density next to ring of c/$c''$ subunits (51). In this study, our immunoprecipitation data showed that both Ac45 and Ac45/C co-precipitated with these $V_o$ subunits in vitro. The IP data indicate that both the wild type Ac45 and the C-terminal truncation mutant Ac45/C can interact with the $V_o$ subunits and are incorporated into the $V_o$ subcomplex. A recent study suggested that tagged a3 subunit did not exhibit the corresponding localization as the authentic protein (24), raising the concern that tagged V-ATPase subunits may cause misfolding or mislocalization. However, other groups have demonstrated that GFP-tagged a3 and other a isoforms localize to the proper intracellular compartments (52, 53). Moreover, studies have used epitope-tagged V-ATPase subunits to rescue the various defective phenotypes caused by knock out of the corresponding V-ATPase subunits in yeast and fly (54) and osteoclasts (37) as well as in immunoprecipitation assays for the identification of interacting V-ATPase subunits (55–59).

V-ATPases are large multisubunit complexes where their correct assembly into functional units requires dedicated assembly factors for orchestrating the assembly events within the endoplasmic reticulum (60). In yeast, several endoplasmic reticulum assembly factors, including Vma12, Vma21, and Vma22, are responsible for $V_o$ domain assembly, an event that occurs independently from $V_i$ assembly event (60, 61). However, at present, the mammalian homologues of these chaperones remain to be identified. In addition,
how different V₀ subunits associate under physiological conditions remains unclear. Although our data suggest that Ac45 is incorporated into the V₀ complex through its association with subunits a3, c, and c', the fact of an incomplete co-localization between Ac45 and a3 could not conclude that Ac45 is a functional essential subunit of the osteoclastic V-ATPases.

Nevertheless, using BRET analysis, we demonstrated that Ac45 is in close proximity with V₀ subunits c'> c > a3 > d. These findings are in line with the notion that Ac45 is tightly affiliated with the proteolipid c/c' ring proposed by Wilkens and Forgac (62) based on their three-dimensional structure analysis of the V₀ domain. The high BRET signal for subunit c' may reflect the close association of Ac45 within this ring. Interestingly deletion of the c-terminal of Ac45 (Ac45ΔC) dramatically decreased its association with c'. Significant reduction, albeit not complete inhibition, in the interaction between Ac45ΔC and c' suggests that the C-terminal domain may only account for part of the Ac45-c' interacting domain. Additional interacting elements within Ac45ΔC may enable c' to remain in close proximity, although not as efficient as the wild type Ac45. In addition, the deletion of the C-terminal of Ac45 also altered the affinity for subunits a3 and d, suggesting that the loss of the C-terminal may also alter the conformation of Ac45, thus increasing its proximity and association with subunits a3 and d. Future investigations will focus on elucidating the precise Ac45 structural domains required for V-ATPase subunit interactions.

Previous modeling studies have demonstrated that the asymmetric protein ring (c, c', c") and the C terminus of a) of the V₀ domain exists with two small openings on the luminal side and one large opening on the cytoplasmic side (62). A globular protein and two cross-linked and elongated proteins have been predicted to cover the central pore of luminal side and cytoplasmic opening, respectively. In the same study, Ac45 has been suggested to be a mass located and covering the luminal side, whereas the N terminus of a3 and d is localized in a way that covers the gap on the cytoplasmic side of asymmetric proteolipid ring (62). In addition, the rotation of the proteolipid ring relative to the a subunit drives the active transport of protons across the limiting membrane, an event of which is precisely manipulated by conformational rearrangements of the subunits (a and d) and the c/c" proteolipid rotary ring (60, 62). The three-dimensional resolution of this model of the structure of the V₀ domain, together with our BRET results, suggests that the C terminus of Ac45 may play an important role in covering the luminal opening of the proteolipid ring and is required for the correct conformational rearrangement of V₀ domain during proton translocation. Taken as such, the C-terminal deletion of Ac45, although it does not affect the assembly of the V₀ domain, may actually impair the V₀ rotary mechanism, thus perturbing the stability and efficiency of the V-ATPase complex. This may account for the reduction, albeit not complete inhibition, of osteoclastic bone resorption observed in vitro.

Overall, based on these findings together with the previously predicted model of the V₀ domain (18), we proposed a revised structural model of Ac45 with other subunits of the V₀ domain (Fig. 6). Ac45 appears to closely associate with the c' subunit through its C-terminal tail, whereas the Ac45 N-terminal region, which has been predicted to be located within the lumen (51), may serve to anchor Ac45 with a3. According to current models, rotational catalysis requires relative rotation of the c/c" proteolipid ring relative to the a subunit. The interaction between Ac45 and c", as modeled in Fig. 6 may modulate rotation of the c/c" ring and rotational catalysis. Truncation of the C-terminal tail of Ac45 results in an altered association configuration with the V₀ complex that might account for malfunctions of V-ATPase during osteoclastic bone resorption.

Acknowledgments—We thank Drs. Lin Huang and Karin Kroeger for expert technical assistance.

REFERENCES

1. Teitelbaum, S. L. (2000) Science 289, 1504–1508
2. Blair, H. C., Teitelbaum, S. L., Ghiselli, R., and Gluck, S. (1989) Science 245, 855–857
3. Pavlos, N. J., Xu, J., Riedel, D., Yeoh, J. S. G., Teitelbaum, S. L., Papadimitriou, J. M., Jahn, R., Ross, F. P., and Zheng, M. H. (2005) Mol. Cell. Biol. 25, 5253–5269
4. Zhao, H., Laitala-Leinonen, T., Parikka, V., and Vaananen, H. K. (2001) J. Biol. Chem. 276, 39295–39302
5. Baron, R., Neff, L., Louvard, D., and Courtoy, P. J. (1985) J. Cell Biol. 101, 2210–2222
6. Baron, R. (1989) Anat. Rec. 224, 317–324
7. Vaananen, H. K., Zhao, H., Mulari, M., and Halleen, J. M. (2000) J. Cell Sci. 113, 377–381
8. Chatterjee, D., Chakraborty, M., Leit, M., Neff, L., Jamsa-Kellokumpu, S., Fuchs, R., and Baron, R. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 6257–6261
9. Li, Y. P., Chen, W., Liang, Y., Li, E., and Stashenko, P. (1999) Nat. Genet. 23, 447–451
10. Sundquist, K. T., and Marks, S. C., Jr. (1994) J. Bone Miner. Res. 9, 1575–1582
11. Xu, J., Peng, H. T., Wang, C., Yip, K. H., Pavlos, N., Papadimitriou, J. M., Wood, D., and Zheng, M. H. (2003) J. Cell. Biochem. 88, 1256–1264
12. Frattini, A., Orchard, P. I., Sobacchi, C., Giliani, S., Abinun, M., Mattsson, J. P., Keeling, D. J., Andersson, A–K., Wallbrandt, P., Zucca, L., Notarangelo, L. D., Vezzoni, P., and Villa, A. (2000) Nat. Genet. 25, 343–346
13. Kornak, U., Schulz, A., Friedrich, W., Ulhhaas, S., Kremens, B., Voit, T., Hasan, C., Bode, U., Jentsch, T. J., and Kubisch, C. (2000) Hum. Mol. Genet. 9, 2059–2063
14. Michigami, T., Kageyama, T., Satomura, K., Shima, M., Yamaoka, K., Nakayama, M., and Ozono, K. (2002) Bone 30, 436–439
15. Scimeca, J.-C., Quincey, D., Parrinello, H., Romate, D., Groseorge, J.,
Ac45 in Osteoclastic Bone Resorption

Gaudray, P., Philip, N. A., and Georges F. Carle, F. (2003) *Hum. Mutat.* **21**, 151–157

16. Xu, J., Cheng, T., Feng, H. T., Pavlos, N. J., and Zheng, M. H. (2007) *Histol. Histopathol.* **22**, 443–454

17. Stevens, T. H., and Forgac, M. (1997) *Annu. Rev. Cell Dev. Biol.* **13**, 779–808

18. Forgac, M. (1999) *J. Biol. Chem.* **274**, 12951–12954

19. Grinstein, S., Nanda, A., Lukacs, G., and Rotstein, O. (1992) *J. Exp. Biol.* **172**, 179–192

20. Swallow, C. I., Grinstein, S., Sudsbury, R. A., and Rotstein, O. D. (1993) *J. Cell. Biol.* **157**, 453–460

21. Arai, H., Terres, G., Pink, S., and Forgac, M. (1988) *J. Biol. Chem.* **263**, 8796–8802

22. Perin, M. S., Fried, V. A., Stone, D. K., Xie, X. S., and Sudhof, T. C. (1991) *J. Biol. Chem.* **266**, 3877–3881

23. Nishi, T., and Forgac, M. (2000) *J. Biol. Chem.* **275**, 6824–6830

24. Toyomura, T., Oka, T., Yamaguchi, C., Wada, Y., and Futai, M. (2000) *J. Biol. Chem.* **275**, 8760–8765

25. Oka, T., Murata, Y., Namba, M., Yoshimizu, T., Toyomura, T., Yamamoto, A., Sun-Wada, G. H., Hamasaki, N., Wada, Y., and Futai, M. (2001) *J. Biol. Chem.* **276**, 40050–40054

26. Nelson, N. (1992) *J. Exp. Biol.* **172**, 149–153

27. Adachi, I., Puopolo, K., Marquez-Sterling, N., Arai, H., and Forgac, M. (1990) *J. Biol. Chem.* **265**, 967–973

28. Supek, F., Supekova, L., Mandiyan, S., Pan, Y. C., Nelson, H., and Nelson, N. (1994) *J. Biol. Chem.* **269**, 24102–24106

29. Xu, J., Tan, J. W., Huang, L., Gao, X. H., Laird, R., Liu, D., Wysocki, S., and Zheng, M. H. (2000) *J. Bone Miner. Res.* **15**, 2178–2186

30. Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) *Molecular Cloning: A Laboratory Manual*, 2nd Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY

31. Lange, P. F., Wartosch, L., Jentsch, T. J., and Fuhrmann, J. C. (2006) *Nature* **440**, 220–223

32. Morita, S., Kojima, T., and Kitamura, T. (2000) *Gene Ther.* **7**, 1063–1066

33. Yip, K. H., Feng, H., Pavlos, N. J., Zheng, M. H., and Xu, J. (2006) *Am. J. Pathol.* **169**, 503–514

34. Kroeger, K. M., Hanyaloglu, A. C., Seeger, R. M., Miles, L. E., and Eidne, K. A. (2001) *J. Biol. Chem.* **276**, 12736–12743

35. Holthuis, J. C., Jansen, E. J., Schoonderwoert, V. T., Burbach, J. P., and Martens, G. J. (1999) *Eur. J. Biochem.* **262**, 484–491

36. Hung, H., Tsai, M. J., Wu, H. C., and Lee, E. H. (2000) *Brain Res. Mol. Brain Res.* **75**, 330–336

37. Lee, S. H., Rho, J., Jeong, D., Sul, J. Y., Kim, T., Kim, N., Kang, J. S., Miyamoto, T., Suda, T., Lee, S. K., Pignolo, R. J., Koczon-Jaremko, B., Lorenzo, J., and Choi, Y. (2006) *Nat. Med.* **12**, 1403–1409

38. Jansen, E. J., Holthuis, J. C., McGrouther, C., Burbach, J. P., and Martens, G. J. (1998) *J. Cell Sci.* **111**, 2999–3006

39. Laitala-Leinonen, T., and Vaananen, H. K. (1999) *Antisense Nucleic Acid Drug Dev.* **9**, 155–169

40. Nelson, N. (1992) *J. Bioenerg. Biomembr.* **24**, 407–414

41. Lee, B. S., Gluck, S. L., and Holliday, L. S. (1999) *J. Biol. Chem.* **274**, 29164–29171

42. Nakamura, T., Takahashi, N., Udagawa, N., Moriyama, Y., Kurokawa, T., Jimi, E., Sasaki, T., and Suda, T. (1997) *FEBS Lett.* **401**, 207–212

43. Toyomura, T., Murata, Y., Yamamoto, A., Oka, T., Sun-Wada, G. H., Wada, Y., and Futai, M. (2003) *J. Biol. Chem.* **278**, 22023–22030

44. Vitavskova, O., Wieczorek, H., and Merzendorfer, H. (2003) *J. Biol. Chem.* **278**, 18499–18505

45. Holliday, L. S., Lu, M., Lee, B. S., Nelson, R. D., Solivan, S., Zhang, L., and Gluck, S. L. (2000) *J. Biol. Chem.* **275**, 32331–32337

46. Dow, J., Davies, S., Guo, Y., Graham, S., Finbow, M., and Kaiser, K. (1997) *J. Exp. Biol.* **200**, 237–245

47. Inoue, H., Noumi, T., Nagata, M., Murakami, H., and Kanazawa, H. (1999) *Biochim. Biophys. Acta* **1413**, 130–138

48. Oka, T., and Futai, M. (2000) *J. Biol. Chem.* **275**, 29556–29561

49. Sun-Wada, G. H., Murata, Y., Yamamoto, A., Kanazawa, H., Wada, Y., and Futai, M. (2000) *Dev. Biol.* **228**, 315–325

50. Schoonderwoert, V. T., and Martens, G. J. (2002) *Mol. Membr. Biol.* **19**, 67–71

51. Wilkens, S., Vasiliev, E., and Forgac, M. (1999) *J. Biol. Chem.* **274**, 31804–31810

52. Dettmer, J., Hong-Hermesdorf, A., Stierhof, Y. D., and Schumacher, K. (2006) *Plant Cell* **18**, 715–730

53. Wassmer, T., Kissmehl, R., Cohen, J., and Plattner, H. (2006) *Mol. Biol. Cell* **17**, 917–930

54. Du, J., Kean, L., Allan, A. K., Southall, T. D., Davies, S. A., McInerny, C. J., and Dow, J. A. (2006) *J. Cell Sci.* **119**, 2542–2551

55. Hurtado-Lorenzo, A., Skinner, M., El Amann, J., Futai, M., Sun-Wada, G. H., Bourgoin, S., Casanova, J., Wildeman, A., Bechoua, S., Aussiello, D. A., Brown, D., and Marshansky, V. (2006) *Nat. Cell Biol.* **8**, 124–136

56. Ohira, M., Smardon, A. M., Charsky, C. M. H., Liu, J., Tarsio, M., and Kane, P. M. (2006) *J. Biol. Chem.* **281**, 22752–22760

57. Sambade, M., and Kane, P. M. (2004) *J. Biol. Chem.* **279**, 17361–17365

58. Nogrette, E. E., Borthwick, K. J., Al-Lamki, R. S., Yu, S., Smith, A. N., and Karet, F. E. (2007) *J. Biol. Chem.* **282**, 14421–14427

59. Sun-Wada, G. H., Yoshimizu, T., Imai-Senga, Y., Wada, Y., and Futai, M. (2003) *Gene (Amst.)* **302**, 147–153

60. Forgac, M. (2007) *Nat. Rev. Mol. Cell Biol.* **8**, 917–929

61. Nishi, T., and Forgac, M. (2002) *Nat. Rev. Mol. Cell Biol.* **3**, 94–103

62. Wilkens, S., and Forgac, M. (2001) *J. Biol. Chem.* **276**, 44064–44068